Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Mccoll, Gawain ^a   Roberts, Blaine R ^a   Pukala, Tara L ^b   Kenche, Vijaya B ^a,c   Roberts, Christine M ^d   Link, Christopher D ^d   Ryan, Timothy M ^a   Masters, Colin L ^a   Barnham, Kevin J ^a,c   Bush, Ashley I ^a   Cherny, Robert A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

8 hydroxyquinoline; Alzheimer's disease; Amyloid beta peptide; Caenorhabditis elegans; PBT2 and drug screen

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; NEUROPROTECTIVE AGENT; PBT 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAENORHABDITIS ELEGANS; COGNITION; CONTROLLED STUDY; DRUG SCREENING; IN VIVO STUDY; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PREDICTIVE VALUE; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CLIOQUINOL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS;

ANIMALIA; CAENORHABDITIS ELEGANS;

EID: 84869210360     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-57     Document Type: Article

References (37)

1. What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases? Teschendorf D, Link CD, Mol Neurodegener 2009 4 38 50 10.1186/1750-1326-4-38 19785750
2. Different 8-hydroxyquinolines protect models of TDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. Tardiff DF, Tucci ML, Caldwell KA, Caldwell GA, Lindquist S, J Biol Chem 2012 287 4107 4120 10.1074/jbc.M111.308668 22147697
3. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, et al. Neuron 2008 59 43 55 10.1016/j.neuron.2008.06. 018 18614028
4. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, et al. Lancet Neurol 2008 7 779 786 10.1016/S1474-4422(08)70167-4 18672400
5. The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, Greenough MA, Volitakis I, Adlard PA, Cherny RA, et al. J Neurochem 2011 119 220 230 10.1111/j.1471-4159.2011.07402.x 21797865
6. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K, Proc Natl Acad Sci USA 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021
7. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Haass C, Selkoe DJ, Cell 1993 75 1039 1042 10.1016/0092-8674(93)90312-E 8261505
8. Alzheimer's disease: the amyloid cascade hypothesis. Hardy JA, Higgins GA, Science 1992 256 184 185 10.1126/science.1566067 1566067
9. The Caenorhabditis elegans Aß1-42 model of Alzheimer disease predominantly expresses Aß3-42. McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherny RA, Bush AI, J Biol Chem 2009 284 22697 22702 10.1074/jbc.C109.028514 19574211
10. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Link CD, Proc Natl Acad Sci USA 1995 92 9368 9372 10.1073/pnas.92.20. 9368 7568134
11. Improved prediction of signal peptides: SignalP 3.0. Bendtsen JD, Nielsen H, von Heijne G, Brunak S, J Mol Biol 2004 340 783 795 10.1016/j.jmb.2004.05. 028 15223320
12. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. Styren SD, Hamilton RL, Styren GC, Klunk WE, J Histochem Cytochem 2000 48 1223 1232 10.1177/002215540004800906 10950879
13. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Nat Med 2008 14 837 842 10.1038/nm1782 18568035
14. Opposing activities protect against age-onset proteotoxicity. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A, Science 2006 313 1604 1610 10.1126/science.1124646 16902091
15. Daf-16 integrates developmental and environmental inputs to mediate aging in the nematode Caenorhabditis elegans. Henderson ST, Johnson TE, Current biology: CB 2001 11 1975 1980 10.1016/S0960-9822(01)00594-2 11747825
16. Direct observation of stress response in Caenorhabditis elegans using a reporter transgene. Link CD, Cypser JR, Johnson CJ, Johnson TE, Cell Stress Chaperones 1999 4 235 242 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2 10590837
17. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K, Acta Neuropathol 2010 120 185 193 10.1007/s00401-010-0690-1 20419305
18. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K, Arch Biochem Biophys 1993 301 41 52 10.1006/abbi.1993.1112 8442665
19. Differences between vascular and plaque core amyloid in Alzheimer's disease. Prelli F, Castano E, Glenner GG, Frangione B, J Neurochem 1988 51 648 651 10.1111/j.1471-4159.1988.tb01087.x 3292706
20. A novel substrate for analyzing Alzheimer's disease gamma-secretase. Lichtenthaler SF, Multhaup G, Masters CL, Beyreuther K, FEBS Lett 1999 453 288 292 10.1016/S0014-5793(99)00730-9 10405162
21. Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification. Minniti AN, Rebolledo DL, Grez PM, Fadic R, Aldunate R, Volitakis I, Cherny RA, Opazo C, Masters C, Bush AI, Inestrosa NC, Mol Neurodegener 2009 4 2 10.1186/1750-1326-4-2 19126228
22. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL, Ann Neurol 1999 46 860 866 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M 10589538
23. Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Tew DJ, Bottomley SP, Smith DP, Ciccotosto GD, Babon J, Hinds MG, Masters CL, Cappai R, Barnham KJ, Biophys J 2008 94 2752 2766 10.1529/biophysj.107.119909 18065467
24. Solution state characterization of amyloid beta-derived diffusible ligands. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, et al. Biochemistry 2006 45 15157 15167 10.1021/bi061850f 17176037
25. The role of metallobiology and amyloid-beta peptides in Alzheimer's disease. Roberts BR, Ryan TM, Bush AI, Masters CL, Duce JA, J Neurochem 2012 120 Suppl 1 149 166 22121980
26. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Alavez S, Vantipalli MC, Zucker DJ, Klang IM, Lithgow GJ, Nature 2011 472 226 229 10.1038/nature09873 21451522
27. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Drake J, Link CD, Butterfield DA, Neurobiol Aging 2003 24 415 420 10.1016/S0197- 4580(02)00225-7 12600717
28. In vivo aggregation of beta-amyloid peptide variants. Fay DS, Fluet A, Johnson CJ, Link CD, J Neurochem 1998 71 1616 1625 9751195
29. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, et al. J Biol Chem 2006 281 17670 17680 10.1074/jbc.M602487200 16648635
30. Wood W, The Nematode Caenorhabditis elegans Cold Spring Harbor, NY, USA: Cold Spring Harbor Laboratory Press 1988
31. Culture of embryonic C. elegans cells for electrophysiological and pharmacological analyses. Bianchi L, Driscoll M, WormBook 2006 http://www.wormbook.org
32. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, et al. Nature 1996 383 710 713 10.1038/383710a0 8878479
33. Electrophoretic separation of betaA4 peptides (1-40) and (1-42). Klafki HW, Wiltfang J, Staufenbiel M, Anal Biochem 1996 237 24 29 10.1006/abio.1996. 0195 8660532
34. The genetics of Caenorhabditis elegans. Brenner S, Genetics 1974 77 71 94 4366476
35. Tricine-SDS-PAGE. Schagger H, Nat Protoc 2006 1 16 22 10.1038/nprot.2006.4 17406207
36. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Link CD, Johnson CJ, Fonte V, Paupard M, Hall DH, Styren S, Mathis CA, Klunk WE, Neurobiol Aging 2001 22 217 226 10.1016/S0197-4580(00)00237-2 11182471
37. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Newcombe RG, Stat Med 1998 17 857 872 10.1002/(SICI)1097- 0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E 9595616